Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Takehiro Kawashiri, Daisuke Kobayashi, Mayako Uchida, Shiori Hiromoto, Masashi Inoue, Hajime Ikeda, Mizuki Inoue, Takao Shimazoe
Formato:	article
Lenguaje:	EN
Publicado:	Canadian Society for Pharmaceutical Sciences 2021
Materias:	Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/cc3f6b3c7d0942a7bbb6d685e86a87c2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc3f6b3c7d0942a7bbb6d685e86a87c2
record_format	dspace
spelling	oai:doaj.org-article:cc3f6b3c7d0942a7bbb6d685e86a87c22021-12-02T17:58:08ZAnalysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)10.18433/jpps318621482-1826https://doaj.org/article/cc3f6b3c7d0942a7bbb6d685e86a87c22021-10-01T00:00:00Zhttps://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/31862https://doaj.org/toc/1482-1826 Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematological malignancy with different drugs is scarce. This study aimed to evaluate the incidence of leukemia and myelodysplastic syndrome in patients with solid tumors, including breast, colon, gastric, pancreatic, small cell lung, non-small cell lung, esophageal, ovarian, cervical, and endometrial cancers. Methods: Using the United States Food and Drug Administration Adverse Event Reporting System, we analyzed the reporting rates, reporting odds ratios, and the reporting onset times of secondary leukemia and myelodysplastic syndrome for each drug used. Results: The leukemia reporting rates were higher in breast, small cell lung, ovarian, and endometrial cancers than in other cancers, and the myelodysplastic syndrome reporting rates were higher in ovarian and endometrial cancers than in other cancers. For each cancer type, the reporting odds ratios of cytocidal anticancer agents, such as taxanes, anthracyclines, alkylating agents, platinum, and topoisomerase inhibitors, were higher than those of other drugs. Alternatively, the reporting odds ratios of molecular targeted drugs and immune checkpoint inhibitors were not higher than those of other drugs. Approximately half of the cases of leukemia and myelodysplastic syndrome were reported within 1 to 4 years after chemotherapy. Conclusions: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens. Takehiro KawashiriDaisuke KobayashiMayako UchidaShiori HiromotoMasashi InoueHajime IkedaMizuki InoueTakao ShimazoeCanadian Society for Pharmaceutical SciencesarticleTherapeutics. PharmacologyRM1-950Pharmacy and materia medicaRS1-441ENJournal of Pharmacy & Pharmaceutical Sciences, Vol 24 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441
spellingShingle	Therapeutics. Pharmacology RM1-950 Pharmacy and materia medica RS1-441 Takehiro Kawashiri Daisuke Kobayashi Mayako Uchida Shiori Hiromoto Masashi Inoue Hajime Ikeda Mizuki Inoue Takao Shimazoe Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
description	Purpose: As the prognosis of cancer patients deteriorates, secondary carcinogenesis after chemotherapy, especially secondary hematological malignancies, becomes a serious problem. However, information on the frequency and time of onset of secondary hematological malignancies and the risk of hematological malignancy with different drugs is scarce. This study aimed to evaluate the incidence of leukemia and myelodysplastic syndrome in patients with solid tumors, including breast, colon, gastric, pancreatic, small cell lung, non-small cell lung, esophageal, ovarian, cervical, and endometrial cancers. Methods: Using the United States Food and Drug Administration Adverse Event Reporting System, we analyzed the reporting rates, reporting odds ratios, and the reporting onset times of secondary leukemia and myelodysplastic syndrome for each drug used. Results: The leukemia reporting rates were higher in breast, small cell lung, ovarian, and endometrial cancers than in other cancers, and the myelodysplastic syndrome reporting rates were higher in ovarian and endometrial cancers than in other cancers. For each cancer type, the reporting odds ratios of cytocidal anticancer agents, such as taxanes, anthracyclines, alkylating agents, platinum, and topoisomerase inhibitors, were higher than those of other drugs. Alternatively, the reporting odds ratios of molecular targeted drugs and immune checkpoint inhibitors were not higher than those of other drugs. Approximately half of the cases of leukemia and myelodysplastic syndrome were reported within 1 to 4 years after chemotherapy. Conclusions: Our study clarified the risks of leukemia and myelodysplastic syndrome for several anticancer drugs in patients with solid tumors. Our data may aid in the assessment of the risks of secondary leukemia and myelodysplastic syndrome when medical oncologists, clinical pharmacists, and patients select chemotherapy regimens.
format	article
author	Takehiro Kawashiri Daisuke Kobayashi Mayako Uchida Shiori Hiromoto Masashi Inoue Hajime Ikeda Mizuki Inoue Takao Shimazoe
author_facet	Takehiro Kawashiri Daisuke Kobayashi Mayako Uchida Shiori Hiromoto Masashi Inoue Hajime Ikeda Mizuki Inoue Takao Shimazoe
author_sort	Takehiro Kawashiri
title	Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
title_short	Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
title_full	Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
title_fullStr	Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
title_full_unstemmed	Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)
title_sort	analysis of secondary leukemia and myelodysplastic syndrome after chemotherapy for solid organ tumors using the food and drug administration adverse event reporting system (faers)
publisher	Canadian Society for Pharmaceutical Sciences
publishDate	2021
url	https://doaj.org/article/cc3f6b3c7d0942a7bbb6d685e86a87c2
work_keys_str_mv	AT takehirokawashiri analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT daisukekobayashi analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT mayakouchida analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT shiorihiromoto analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT masashiinoue analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT hajimeikeda analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT mizukiinoue analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers AT takaoshimazoe analysisofsecondaryleukemiaandmyelodysplasticsyndromeafterchemotherapyforsolidorgantumorsusingthefoodanddrugadministrationadverseeventreportingsystemfaers
_version_	1718379073444511744

Analysis of Secondary Leukemia and Myelodysplastic Syndrome After Chemotherapy for Solid Organ Tumors Using the Food and Drug Administration Adverse Event Reporting System (FAERS)

Ejemplares similares